Illumina launches 18‑month NovaSeq X upgrades to boost throughput, accuracy and workflow flexibility

Illumina unveils 18-month NovaSeq X upgrade roadmap

Illumina is rolling out an 18-month roadmap of software, chemistry and consumable upgrades for its NovaSeq X high-throughput sequencer, aiming to boost throughput, accuracy and operational flexibility across the company’s installed base. The program, which begins deploying across 8,901 NovaSeq X instruments globally in the coming weeks, increases per-run output by about 40% to as much as 35 billion reads and targets a step-change in base-call quality toward Q70 for the first time. Illumina also cites a roughly 30% acceleration in run speed and introduces staggered run starts, new flow-cell architectures and flexible workflow modes to shorten turnaround and better match capacity to varying sample arrival.

The company frames the enhancements as a compounded upgrade path where iterative software and chemistry updates together deliver higher daily productivity and broader protocol compatibility without requiring new hardware purchases. By boosting per-run yield and improving base-call accuracy, Illumina says laboratories can increase multiplexing, run deeper whole-genome sequencing on a single instrument and detect lower-frequency variants that are important for sensitive clinical and population studies. Staggered starts and new flow cells are designed to reduce instrument idle time and permit mixed-run scheduling, which Illumina expects will improve utilization and shorten sample-to-answer times for high-volume facilities.

Deployment is global and staged, with Illumina positioning the NovaSeq X as a reinforced gold-standard platform for research, clinical and population-scale sequencing programs. The company emphasizes that the combined improvements lower per-sample cost through higher yields and faster runs, while Q70-level accuracy is expected to enable ultrassensitive assays used in precision medicine and oncology. Illumina presents the roadmap as delivering compounded value to customers seeking faster, more cost-effective and higher-accuracy sequencing for demanding applications.

Operational impact for laboratories

Laboratories receive operational options that include staggered run-starts and flexible workflow modes that allow sequencing centers to align instrument capacity with variable sample inflow. Illumina anticipates these features reduce idle time, enable better throughput planning and shorten project timelines for large-scale sequencing efforts.

Scientific and clinical implications

Higher per-run yields and Q70-level accuracy position the platform to support ultradeep sequencing, enhanced sample multiplexing and improved detection of low-frequency variants, which are critical for precision-medicine assays, population genomics and clinical diagnostics. Illumina frames the upgrades as enabling broader application of deep whole-genome sequencing on existing instruments.